NasdaqGM:ZLABBiotechs
Amgen-Backed DLL3 Combo Trial Could Be A Game Changer For Zai Lab (ZLAB)
Zai Lab Limited recently announced a global clinical trial collaboration with Amgen Inc. to test Zai Lab’s DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan (zoci) in combination with Amgen’s IMDELLTRA in a Phase 1b study for patients with extensive-stage small cell lung cancer.
This agreement, under which Amgen sponsors the study while Zai Lab retains full ownership of zoci and supplies the study drug, signals external confidence in Zai Lab’s oncology research platform and its...